Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Abbott

More Like This

mAbxience and Biosidus Sign CDMO Agreement for the Manufacture of Agalsidase Beta for the Treatment of Fabry Disease

PR Newswire associated0

mAbxience Appoints Jurgen Van Broeck as New CEO

PR Newswire associated0

mAbxience Announces European Commission Approval of Denosumab Biosimilars

PR Newswire associated0

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

PR Newswire associated0

The Department of Health - Abu Dhabi and Abbot Unite to Manufacture Pharmaceuticals Locally in Abu Dhabi

PR Newswire associated0

SWIXX BIOPHARMA EXPANDS TO LATIN AMERICA THROUGH A STRATEGIC ACQUISITION AND COMBINATION WITH BIOPAS

Prestige Biopharma and Biosidus Enter Exclusive License Agreement for Tuznue® Commercialization in Latin America

Representatives from the Local Content & Government Procurement Authority (LCGPA) and Boston Oncology Arabia at the Global Health Exhibition 2025 in Riyadh, following the signing of an agreement to localize the manufacturing of advanced biologic medicines. The partnership builds on Boston Oncology Arabia’s fully integrated Saudi operations and its leadership in transferring global biopharma expertise to strengthen national drug security, expand local value creation, and deliver sustainable access to high-quality biologic therapies in line with Vision 2030.

BOSTON ONCOLOGY ARABIA and LOCAL CONTENT & GOVERNMENT PROCUREMENT AUTHORITY Sign Agreement to Localize Advanced Biologic Medicines in Saudi Arabia